Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients

NCT ID: NCT06778538

Last Updated: 2025-01-16

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 40 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-07-01
• Study Completion Date: 2024-11-20

Brief Summary

This study aims to investigate the role of HPGD in clear cell renal cell carcinoma (ccRCC). Specifically, it will focus on HPGD's impact on proliferation, epithelial-mesenchymal transition (EMT), and prognosis. The study will analyze gene expression data from clinical samples and use techniques like RT-qPCR, Western blotting, and immunohistochemistry to assess HPGD expression levels. Additionally, the research will explore the relationship between HPGD and patient survival outcomes. By elucidating HPGD's contribution to cancer progression, the study seeks to identify potential therapeutic targets for improving renal cancer treatment.

Detailed Description

This study is designed to comprehensively explore the role of 15-hydroxyprostaglandin dehydrogenase ( HPGD) in clear cell renal cell carcinoma development and progression. HPGD has been implicated in various cancers, with evidence suggesting its involvement in tumorigenesis, EMT, and poor prognosis. However, its specific function n clear cell renal cell carcinoma (ccRCC) is still unclear. This research will analyze clinical samples, including tumor tissues and normal adjacent tissues, to evaluate HPGD expression through a combination of advanced laboratory techniques such as quantitative real-time PCR (qRT-PCR), Western blotting, immunohistochemistry (IHC) and RNA sequencing.

Furthermore, HPGD-interacting proteins were predicted using STRING and TCGA data, followed by PCR, Western blot validation, and IHC. Mechanistically, HPGD positively correlated with the solute carrier organic anion transporter 2A1 (SLCO2A1), and SLCO2A1 knockdown partially attenuated the tumor-suppressive effects of HPGD overexpression..

This study underscores the tumor-suppressive role of HPGD in ccRCC, highlighting its capacity to hinder cell proliferation and EMT via its interaction with SLCO2A1. Targeting the HPGD-SLCO2A1 axis may offer a promising novel therapeutic approach for ccRCC management.

Conditions

Clear Cell Renal Cell Carcinoma (ccRCC)

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: RETROSPECTIVE

Interventions

Immunohistochemistry; WB; PCR

The intervention will specifically focus on evaluating the role of HPGD in patients with clear cell renal cell carcinoma by classifying them into high-low expression groups based on median HPGD expression values by immunohistochemical scores for prognostic analysis. Protein and RNA were extracted from collected ccRCC tissues for expression verification.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

Adults aged 18 years or older. Histologically confirmed diagnosis of clear cell renal cell carcinoma . Measurable disease as per RECIST criteria. Adequate organ function as defined by laboratory tests (e.g., liver, kidney, and hematologic function).

HPGD expression level determined via biopsy or previous analysis. Written informed consent provided.

Exclusion Criteria

History of other malignancies within the past 5 years, excluding non-melanoma skin cancer or in situ carcinoma.

Prior treatment with HPGD inhibitors or similar targeted therapies. Active or uncontrolled infections. Pregnant or breastfeeding women. Known autoimmune disorders or conditions requiring immunosuppressive therapy. Inability to comply with the study protocol or procedures.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lanzhou University Second Hospital

OTHER

Sponsor Role: collaborator

Shang Panfeng

OTHER

Sponsor Role: lead

Responsible Party

Shang Panfeng

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Lanzhou University Second Hospital

Lanzhou, Gansu, China

Countries

China

References

Monteleone NJ, Moore AE, Iacona JR, Lutz CS, Dixon DA. miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer. Sci Rep. 2019 Apr 1;9(1):5405. doi: 10.1038/s41598-019-41862-2.

Reference Type: BACKGROUND

PMID: 30931980 (View on PubMed)

Arima K, Komohara Y, Bu L, Tsukamoto M, Itoyama R, Miyake K, Uchihara T, Ogata Y, Nakagawa S, Okabe H, Imai K, Hashimoto D, Chikamoto A, Yamashita YI, Baba H, Ishimoto T. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1beta from activated macrophages leads to poor prognosis in pancreatic cancer. Cancer Sci. 2018 Feb;109(2):462-470. doi: 10.1111/cas.13467. Epub 2018 Jan 27.

Reference Type: BACKGROUND

PMID: 29224225 (View on PubMed)

Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12098-102. doi: 10.1073/pnas.0603235103. Epub 2006 Jul 31.

Reference Type: BACKGROUND

PMID: 16880406 (View on PubMed)

Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, Koeffler HP. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006 Aug 1;66(15):7818-23. doi: 10.1158/0008-5472.CAN-05-4368.

Reference Type: BACKGROUND

PMID: 16885386 (View on PubMed)

Other Identifiers

2023A-096

Identifier Type: -

Identifier Source: org_study_id